- Conditions
- Metastatic Breast Cancer
- Interventions
- Eribulin Mesylate, Capecitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 13
- States / cities
- Anaheim, California • La Verne, California • Poway, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1729–1752
of 16,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
- Interventions
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Acupuncture
- Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Vulvar Lichen Sclerosus
- Interventions
- The CO2RE® System
- Device
- Lead sponsor
- Candela Corporation
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont
- Conditions
- Breast Cancer
- Interventions
- Temsirolimus, Neratinib
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 4
- States / cities
- Goodyear, Arizona • Los Angeles, California • New York, New York
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Dermagraft(R), Conventional care
- Device · Other
- Lead sponsor
- Organogenesis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 1997
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2037
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Bacterial Infections
- Interventions
- IV Vancomycin plus IV Aztreonam, Ceftaroline
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 15
- States / cities
- Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
- Conditions
- Lung Cancer, Cervical Cancer, Breast Cancer, Colorectal Cancer
- Interventions
- Lay health advisor interactions
- Behavioral
- Lead sponsor
- Nancy Schoenberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,415 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Whitesburg, Kentucky
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Povorcitinib, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more
- Conditions
- Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Breast Neoplasm, Hereditary Neoplastic Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- irofulven
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hair Thinning
- Interventions
- Nutraceuticals (Prototype)
- Dietary Supplement
- Lead sponsor
- Unilever R&D
- Industry
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Neoplasm
- Interventions
- F-18 FES, F-18 FDG
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 90 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer, Ovarian Cancer, Uterine Cancer, Pancreatic Cancer
- Interventions
- Hemp-based CBD, Placebo oral tablet
- Drug · Other
- Lead sponsor
- Main Line Health
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Neoplasms, Skin Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Actinic Keratosis
- Interventions
- LEO 43204, LEO 43204 Vehicle
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Acne
- Interventions
- Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
- Drug
- Lead sponsor
- Callender Center for Clinical Research
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Mitchellville, Maryland • Philadelphia, Pennsylvania
- Conditions
- Psoriasis
- Interventions
- CC-90006, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Anaheim, California • Fair Lawn, New Jersey • Duncansville, Pennsylvania
- Conditions
- Breast Tumor
- Interventions
- GE Logiq E10 clinical ultrasound scanner, Verasonics research scanner
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer, Ovarian Cancer
- Interventions
- Telephone Counseling & Navigation (TCN), Mailed Targeted Print (TP), Usual Care (UC)
- Behavioral · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 668 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
- Conditions
- Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Interventions
- Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
- Device · Other
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland